Apeloa Pharmaceutical Co Ltd (000739) — Capital Reinvestment Ratio
Apeloa Pharmaceutical Co Ltd (000739) has a Capital Reinvestment Ratio of 0.37x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥446.18 Million) in capital expenditures (CN¥166.73 Million). See 000739 equity to assets ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Apeloa Pharmaceutical Co Ltd Capital Reinvestment Ratio (1998–2025)
This chart tracks Apeloa Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 26 annual periods. Check cash flow reinvestment rate of Apeloa Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Apeloa Pharmaceutical Co Ltd (1998–2025)
Year-by-year Capital Reinvestment Ratio for Apeloa Pharmaceutical Co Ltd from 1998 to 2025. For live market cap and broader valuation context, see how much is Apeloa Pharmaceutical Co Ltd worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.31x | CN¥1.23 Billion | CN¥386.21 Million | ▼ -17.7% |
| 2024 | 0.38x | CN¥1.21 Billion | CN¥460.75 Million | ▼ -37.6% |
| 2023 | 0.61x | CN¥1.03 Billion | CN¥630.47 Million | ▲ +59.2% |
| 2022 | 0.38x | CN¥1.33 Billion | CN¥509.11 Million | ▼ -66.5% |
| 2021 | 1.15x | CN¥611.75 Million | CN¥701.92 Million | ▲ +283.4% |
| 2020 | 0.30x | CN¥1.06 Billion | CN¥317.12 Million | ▲ +1178.2% |
| 2019 | 0.02x | CN¥1.36 Billion | CN¥31.85 Million | ▼ -76.1% |
| 2018 | 0.10x | CN¥832.69 Million | CN¥81.62 Million | ▼ -87.4% |
| 2017 | 0.78x | CN¥209.80 Million | CN¥163.42 Million | ▼ -57.6% |
| 2016 | 1.84x | CN¥180.42 Million | CN¥331.35 Million | ▲ +79.2% |
| 2015 | 1.02x | CN¥441.16 Million | CN¥452.06 Million | ▲ +49.2% |
| 2014 | 0.69x | CN¥786.64 Million | CN¥540.22 Million | ▼ -74.1% |
| 2013 | 2.65x | CN¥190.45 Million | CN¥505.01 Million | ▲ +162.3% |
| 2012 | 1.01x | CN¥335.90 Million | CN¥339.59 Million | ▲ +41.4% |
| 2011 | 0.71x | CN¥404.62 Million | CN¥289.21 Million | ▼ -38.1% |
| 2010 | 1.15x | CN¥121.05 Million | CN¥139.81 Million | ▲ +156.9% |
| 2009 | 0.45x | CN¥208.30 Million | CN¥93.66 Million | ▼ -87.8% |
| 2008 | 3.69x | CN¥94.57 Million | CN¥349.04 Million | ▲ +455.7% |
| 2007 | 0.66x | CN¥174.20 Million | CN¥115.70 Million | ▲ +96.7% |
| 2006 | 0.34x | CN¥159.43 Million | CN¥53.84 Million | ▼ -75.7% |
| 2005 | 1.39x | CN¥87.40 Million | CN¥121.65 Million | ▼ -40.4% |
| 2004 | 2.34x | CN¥47.54 Million | CN¥111.07 Million | ▲ +179.4% |
| 2003 | 0.84x | CN¥105.36 Million | CN¥88.09 Million | ▼ -95.0% |
| 2002 | 16.78x | CN¥2.81 Million | CN¥47.23 Million | ▲ +3595.5% |
| 2000 | 0.45x | CN¥7.08 Million | CN¥3.22 Million | ▼ -16.8% |
| 1998 | 0.55x | CN¥30.10 Million | CN¥16.43 Million | — |